Physician profile
Ed Y Atty
NPI 1144260332
$3,355.37
in general payments reported to CMS, 2019-2025
40 companies · $500 in 2025
The $500 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2021: $442 · 2022: $687 · 2023: $338 · 2024: $494 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.95 | 2021-2025 | Botox, Ubrelvy |
| Scilex Pharmaceuticals INC. | $290.41 | 2019-2024 | Ztlido |
| Merz Pharmaceuticals, LLC | $239.90 | 2021-2024 | Xeomin |
| Collegium Pharmaceutical, INC. | $239.81 | 2019-2025 | Belbuca, Xtampza |
| Spr Therapeutics, INC | $201.63 | 2024-2025 | Sprint Pns System |
| Ipsen Biopharmaceuticals, INC | $192.29 | 2022-2025 | Dysport |
| Allergan, INC. | $149.65 | 2019-2022 | |
| Nevro Corp. | $147.38 | 2022-2024 | Senza |
| Fidia Pharma USA INC. | $103.63 | 2019-2024 | Hymovis, Triluron |
| Biohaven Pharmaceutical Holding Company LTD. | $98.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.39 | 2019-2022 | |
| Merz North America, INC. | $90.80 | 2019 | |
| Averitas Pharma INC. | $83.92 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $70.19 | 2021-2022 | |
| Vertiflex, INC. | $69.88 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ed Atty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.